Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis IncfiledCriticalExelixis Inc
Publication of DOP2009000241ApublicationCriticalpatent/DOP2009000241A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invencion proporciona metodos de tratar cancer por la administracion de un compuesto de Formula I, opcionalmente en forma de sus sales farmaceuticamente aceptable, sus solvatos y/o hidratos, en combinacion con otros tratamientos de cancer.The present invention provides methods of treating cancer by administering a compound of Formula I, optionally in the form of its pharmaceutically acceptable salts, its solvates and / or hydrates, in combination with other cancer treatments.
DO2009000241A2007-04-112009-10-09
PI3K-ALFA QUINAXOLINE INHIBITORS FOR CANCER TREATMENT
DOP2009000241A
(en)
USE OF N- (4 - ((3- (2-AMINO-4-PIRIMIDINIL) -2-PIRIDINIL) OXI) PHENYL) -4- (4-METHYL-2-TIENYL) -1-FTALAZINAMINE IN CANCER TREATMENT ANTIMITOTIC AGENT RESISTANT